TheraRadar
← Back
Data updated: Sep 20, 2026

MANKIND PHARMA

Generics
CardiovascularNeurologyRespiratory

MANKIND PHARMA is a generic drug manufacturer focused on Cardiovascular, Neurology, Respiratory.

2001
Since
61
Drugs
-
Trials
3
New Drugs (2yr)

MANKIND PHARMA's Key Drugs

MANKIND PHARMA's key approved drugs from the last 15 years (excludes generics, biosimilars and IV formulations).

No active drugs

MANKIND PHARMA's Recent FDA Approvals

MANKIND PHARMA secured 3 new FDA approvals for novel drugs (NDA/BLA) in the last two years.

ROCURONIUM BROMIDE NDA
2025-10-24
rocuronium bromide
Routine tracheal intubation
FAMOTIDINE NDA
2025-07-16
famotidine
1 INDICATIONS AND USAGE Famotidine tablets are indicated in adult and pediatric patients 40 kg and greater for the treatment of: • active duodenal ulcer (DU). • active gastric ulcer (GU). • symptomatic nonerosive gastroesophageal reflux disease (GERD). • erosive esophagitis due to GERD, diagnosed by biopsy. Famotidine tablets are indicated in adults for the: • treatment of pathological hypersecretory conditions (e.g., Zollinger-Ellison syndrome, multiple endocrine neoplasias). • reduction of the risk of duodenal ulcer recurrence. Famotidine tablets are a histamine-2 (H 2 ) receptor antagonist indicated ( 1 ): In adult and pediatric patients 40 kg and greater for the treatment of: • active duodenal ulcer (DU). • active gastric ulcer. • symptomatic nonerosive gastroesophageal reflux disease (GERD). • erosive esophagitis due to GERD, diagnosed by biopsy. In adults for the: • treatment of pathological hypersecretory conditions (e.g., Zollinger-Ellison syndrome, multiple endocrine neoplasias). • reduction of the risk of DU recurrence.
ROCURONIUM BROMIDE NDA
2025-06-09
rocuronium bromide
Routine tracheal intubation

MANKIND PHARMA's Therapeutic Areas

MANKIND PHARMA's approved drugs and pipeline span 5 therapeutic areas, led by Cardiovascular and Neurology. Weighted by commercial stage — approved drugs count most, then late-stage trials.

Cardiovascular 45%
11 drugs
Neurology 20%
5 drugs
Respiratory 16%
4 drugs
Infectious Disease 12%
3 drugs
Ophthalmology 7%
1 drugs Phase 3: 1

MANKIND PHARMA's Top Competitors

MANKIND PHARMA's closest competitors by therapeutic-area and drug-target overlap include Novartis, GE HEALTHCARE, and Merck. Ranked by overlap in therapeutic areas and drug targets across approved drugs and pipeline.

Novartis big-pharma
Cardiovascular, Ophthalmology, Respiratory
GE HEALTHCARE specialty
Neurology, Cardiovascular, Infectious Disease, Respiratory
Merck big-pharma
Infectious Disease, Cardiovascular, Respiratory
AbbVie big-pharma
Infectious Disease, Neurology, Ophthalmology
LEDERLE big-pharma
Infectious Disease, Cardiovascular, Neurology, Respiratory

MANKIND PHARMA Pipeline Snapshot

MANKIND PHARMA has 1 active clinical program from ClinicalTrials.gov — 1 Phase 3, 0 Phase 2 and 0 Phase 1.

1
Phase 3
0
Phase 2
0
Phase 1

Pro Intelligence Preview

Deep insights for investors and analysts

Revenue Insights

  • • Top drug revenue breakdown
  • • Drug-level revenue analysis

Trial Catalysts

  • • Cardiovascular pipeline focus
  • • Phase 3 readout tracking

Patent Risk

  • • Patent expiration timeline
  • • Revenue at risk analysis

Compare Companies

  • • Side-by-side pipeline analysis
  • • Revenue & market share comparison
Unlock Full Intelligence

Revenue forecasts • Trial milestones • Patent risk modeling